Insights
SEC Staff Issues No-Action Letter for DePIN Token Distributions
LathamTECH in Focus: Navigating Global Antitrust Waters
The 2025 US Government Shutdown: Update on IRS Operations
Report
One Big Beautiful Bill: Key Business and Investment Impacts
The Act makes permanent many expiring TCJA provisions and changes key features of US tax law applicable to businesses and investments.
Latham in Focus Video Series
The Book of Jargon Series – Word of the Day®
The Book of Jargon® is a series of practice area and industry-specific glossaries published by Latham & Watkins.
Discovery
a mechanism of obtaining information from other parties. While Discovery in PTAB Proceedings is generally limited, parties are entitled to Mandatory Initial Disclosures and Routine Discovery. Any Discovery beyond Routine Discovery is considered Additional Discovery. Parties may agree to Additional Discovery or, after receiving Board authorization, a party may file a Motion for Additional Discovery. 37 C.F.R. § 42.51.
Acquisitions and Divestitures (A&D)
a term used to describe a transaction wherein an entity or person purchases or sells an asset, as opposed to a transaction that includes the purchase and/or sale of equity or stock of an entity or a joint venture arrangement.
Nanotechnology
generically refers to synthetic materials that operate on the 1-100 nanometer scale (75,000 times smaller than a human hair). From small fluidic chambers, to sensors, to biochemical switches, to labels, nanotechnology is an active area of therapeutic research.
Line Spacing
the required spacing of lines for documents in PTAB Proceedings. The PTAB imposes specific formatting requirements for filing documents. Double spacing must always be used except for Claim Charts, headings, tables of contents, tables of authorities, indices, signature blocks and certificates of service. Block quotations may be 1.5 spaced, but must be indented from the left and right margins. 37 C.F.R. § 42.6(a)(2).
Point of No Return
Under recent English case law, the Court of Appeal held that the Balance Sheet Test was primarily a test for whether a company had “reached the point of no return”. The Court of Appeal held that a company reaches the Point of No Return when it faces “an incurable deficiency in its assets”.